June 10, 2022 -- Artificial intelligence (AI) developer Tempus is partnering with Eli Lilly to provide broader access to genomic testing to patients with advanced/metastatic non-small cell lung cancer (NSCLC).
The collaboration will use Tempus tests, like the Tempus xT broad-panel genomic sequencing assay that is designed to detect actionable alterations by sequencing tumor samples with matched normal saliva or blood samples. Eli Lilly will help to expand access to genomic testing by removing cost as a barrier for NSCLC patients to receive molecular profiling. In patients for whom tissue is unavailable or is not sufficient to conduct broad-based tissue testing, Tempus' xF liquid biopsy is available as an alternative. Physicians will also be able to order select immunohistochemistry staining, the firms said.